MG53 Preserves Neuromuscular Junction Integrity and Alleviates ALS Disease Progression

Area of Science:

• Muscle physiology
• Neurodegenerative disease research
• Biomolecular repair mechanisms

Background:

• Amyotrophic lateral sclerosis (ALS) is characterized by progressive respiratory muscle weakness, leading to respiratory failure.
• Neuromuscular junction (NMJ) defects and loss are early pathological events in ALS, representing a therapeutic target.
• MG53, a muscle protein, plays a crucial role in plasma membrane repair.

Purpose of the Study:

• To investigate the role of MG53 in repairing NMJ damage in ALS.
• To evaluate the therapeutic potential of systemic MG53 administration in ALS models.

Main Methods:

• Examined diaphragm muscle from ALS mouse models and human patient samples.
• Assessed NMJ integrity and muscle membrane repair.
• Administered recombinant human MG53 protein to ALS mice.

Main Results:

• Diaphragm muscles in ALS models exhibited compromised membrane repair and NMJ integrity, with intracellular MG53 aggregation.
• Systemic MG53 administration protected against diaphragm muscle injury in ALS mice.
• MG53 treatment preserved NMJ integrity and slowed disease progression in ALS mice.

Conclusions:

• MG53 actively repairs NMJ damage, a critical factor in ALS.
• Systemic MG53 protein therapy shows promise for mitigating ALS progression by preserving NMJ integrity and muscle function.